title: Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice.
abstract: In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-α), interleukin one beta (IL-1β), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn's disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn's disease.
authors.forename: Marc
authors.initials: M
authors.lastname: Fakhoury
authors.forename: Michael
authors.initials: M
authors.lastname: Coussa-Charley
authors.forename: Hani
authors.initials: H
authors.lastname: Al-Salami
authors.forename: Imen
authors.initials: I
authors.lastname: Kahouli
authors.affiliation: Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. marc.fakhoury@mail.mcgill.ca.
authors.forename: Satya
authors.initials: S
authors.lastname: Prakash
mesh_terms: D000464:Alginates / Q000737:chemistry; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000737:chemistry; D015415:Biomarkers / Q000378:metabolism; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D003092:Colitis / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D003106:Colon / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000737:chemistry; D018836:Inflammation Mediators / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D020556:Neutrophil Infiltration / Q000187:drug effects; D010316:Particle Size; D009195:Peroxidase / Q000378:metabolism; D011107:Polylysine / Q000031:analogs & derivatives / Q000737:chemistry; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods; D013792:Thalidomide / Q000008:administration & dosage* / Q000737:chemistry; D013997:Time Factors; D014302:Trinitrobenzenesulfonic Acid; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000464:Alginates; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D002214:Capsules; D005765:Gastrointestinal Agents; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; C051546:alginate-polylysine-alginate; C577686:interleukin-6, mouse; D011107:Polylysine; D013792:Thalidomide; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase